Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma ...

Doctors do not usually recommend surgery for multiple myeloma. However, it may be necessary to repair damaged bones, replace bone marrow, or treat spinal cord compression. Surgery to treat ...

WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Genetic tests can show which patients with the blood cancer multiple myeloma ...

Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Multiple myeloma is a rare type of cancer. It starts with the uncontrolled production of plasma cells. These are a type of white blood cell in the bone marrow. Healthy plasma cells make antibodies ...

We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood cell called plasma cells.

Incidentally discovered vertebral fractures are common on scans in general population, but the absolute risk for MM in such ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...